Published in Clin Cancer Res on March 09, 2010
Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development. Mar Drugs (2014) 1.33
ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties. PLoS One (2010) 1.26
Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization. PLoS One (2010) 1.23
Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol (2013) 1.18
The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis. Sci Rep (2012) 1.06
The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer. Nat Cell Biol (2016) 1.02
Ciliary neurotrophic factor induces genes associated with inflammation and gliosis in the retina: a gene profiling study of flow-sorted, Müller cells. PLoS One (2011) 1.01
CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone. Am J Pathol (2011) 0.99
Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature. Pigment Cell Melanoma Res (2012) 0.95
Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. Onco Targets Ther (2013) 0.91
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. J Clin Oncol (2014) 0.84
Expression and immunolocalization of Gpnmb, a glioma-associated glycoprotein, in normal and inflamed central nervous systems of adult rats. Brain Behav (2012) 0.84
Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatr Blood Cancer (2014) 0.83
Primer on tumor immunology and cancer immunotherapy. J Immunother Cancer (2013) 0.82
GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin α5β1 for efficient breast cancer metastasis. Oncogene (2015) 0.81
Breast cancer at bone metastatic sites: recent discoveries and treatment targets. J Cell Commun Signal (2011) 0.81
Differential expression of glycoprotein non-metastatic melanoma protein B (GPNMB) involved in trichostatin A-induced apoptosis in gastric cancer. Int J Clin Exp Med (2014) 0.80
Inhibition of Phosphatase Activity Follows Decline in Sulfatase Activity and Leads to Transcriptional Effects through Sustained Phosphorylation of Transcription Factor MITF. PLoS One (2016) 0.79
Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression. BMC Cancer (2015) 0.79
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer. Breast Cancer (Auckl) (2016) 0.79
Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers. Oncotarget (2016) 0.78
Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies. Oncotarget (2017) 0.78
Beneficial impact of Gpnmb and its significance as a biomarker in nonalcoholic steatohepatitis. Sci Rep (2015) 0.78
Approach to the Triple Negative Breast Cancer in New Drugs Area. Int J Hematol Oncol Stem Cell Res (2016) 0.77
Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer. Cancer Med (2015) 0.77
Concepts and targets in triple-negative breast cancer: recent results and clinical implications. Ther Adv Med Oncol (2016) 0.76
Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model. Endocr Relat Cancer (2016) 0.76
Osteoactivin Promotes Migration of Oral Squamous Cell Carcinomas. J Cell Physiol (2016) 0.75
Osteoactivin (GPNMB) ectodomain protein promotes growth and invasive behavior of human lung cancer cells. Oncotarget (2016) 0.75
Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation. Front Oncol (2015) 0.75
Marine Antibody-Drug Conjugates: Design Strategies and Research Progress. Mar Drugs (2017) 0.75
Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments. Target Oncol (2017) 0.75
Osteoactivin regulates head and neck squamous cell carcinoma invasion by modulating matrix metalloproteases. J Cell Physiol (2017) 0.75
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
A multigenic program mediating breast cancer metastasis to bone. Cancer Cell (2003) 16.86
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
Stromal gene expression predicts clinical outcome in breast cancer. Nat Med (2008) 10.68
Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med (2003) 7.86
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov (2006) 6.88
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell (2012) 4.47
Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature (2009) 4.21
E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell (2002) 3.87
Quantitative proteomics analysis of the secretory pathway. Cell (2006) 3.63
AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab (2012) 3.35
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum (2008) 3.25
Tools for visually exploring biological networks. Bioinformatics (2007) 3.20
Associations with early-life socio-economic position in adult DNA methylation. Int J Epidemiol (2011) 2.67
SP analysis may be used to identify cancer stem cell populations. Exp Cell Res (2006) 2.49
Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest (2004) 2.45
Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell (2003) 2.24
Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry. Appl Immunohistochem Mol Morphol (2009) 2.22
Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol (2012) 2.17
Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res (2006) 2.12
Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A (2009) 2.01
Regulation of endocytosis via the oxygen-sensing pathway. Nat Med (2009) 2.00
Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. Mol Cell (2003) 1.95
miR-378(∗) mediates metabolic shift in breast cancer cells via the PGC-1β/ERRγ transcriptional pathway. Cell Metab (2010) 1.89
Broad epigenetic signature of maternal care in the brain of adult rats. PLoS One (2011) 1.86
Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1. Proc Natl Acad Sci U S A (2012) 1.80
Breast cancer - one term, many entities? J Clin Invest (2011) 1.72
Crosstalk in Met receptor oncogenesis. Trends Cell Biol (2009) 1.70
Simultaneous identification of duplications and lateral gene transfers. IEEE/ACM Trans Comput Biol Bioinform (2011) 1.66
Interaction of CagA with Crk plays an important role in Helicobacter pylori-induced loss of gastric epithelial cell adhesion. J Exp Med (2005) 1.66
Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol Cell Biol (2005) 1.65
Structural basis for ubiquitin-mediated dimerization and activation of the ubiquitin protein ligase Cbl-b. Mol Cell (2007) 1.60
Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res (2011) 1.58
Genome-wide identification of direct target genes implicates estrogen-related receptor alpha as a determinant of breast cancer heterogeneity. Cancer Res (2009) 1.58
Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1. J Biol Chem (2002) 1.57
Adoptive transfer of mesenchymal stromal cells accelerates intestinal epithelium recovery of irradiated mice in an interleukin-6-dependent manner. Cytotherapy (2012) 1.53
The signature of maternal rearing in the methylome in rhesus macaque prefrontal cortex and T cells. J Neurosci (2012) 1.51
Identifying regulatory subnetworks for a set of genes. Mol Cell Proteomics (2005) 1.48
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol (2010) 1.45
Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res (2007) 1.39
Pc2-mediated sumoylation of Smad-interacting protein 1 attenuates transcriptional repression of E-cadherin. J Biol Chem (2005) 1.39
Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions. Mol Biol Cell (2002) 1.34
Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. Nucleic Acids Res (2002) 1.33
Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. Cancer Res (2009) 1.32
Protein kinase C-zeta regulates transcription of the matrix metalloproteinase-9 gene induced by IL-1 and TNF-alpha in glioma cells via NF-kappa B. J Biol Chem (2002) 1.32
Role for Runx1 in the proliferation and neuronal differentiation of selected progenitor cells in the mammalian nervous system. J Neurosci (2005) 1.31
GGA3 functions as a switch to promote Met receptor recycling, essential for sustained ERK and cell migration. Dev Cell (2011) 1.31
HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol Biol Cell (2004) 1.26
ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties. PLoS One (2010) 1.26
Pak4, a novel Gab1 binding partner, modulates cell migration and invasion by the Met receptor. Mol Cell Biol (2009) 1.23
Noninvasive quantitation of human liver steatosis using magnetic resonance and bioassay methods. Eur Radiol (2009) 1.23
The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation. Oncogene (2005) 1.22
Accumulation of multipotent progenitors with a basal differentiation bias during aging of human mammary epithelia. Cancer Res (2012) 1.20
CrkI and CrkII function as key signaling integrators for migration and invasion of cancer cells. Mol Cancer Res (2005) 1.18
PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. J Clin Invest (2011) 1.17
A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation. J Biol Chem (2004) 1.17
Crk associates with a multimolecular Paxillin/GIT2/beta-PIX complex and promotes Rac-dependent relocalization of Paxillin to focal contacts. Mol Biol Cell (2003) 1.16
The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. Proc Natl Acad Sci U S A (2004) 1.15
Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase. J Biol Chem (2008) 1.15
CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer (2010) 1.14
Signaling through ShcA is required for transforming growth factor beta- and Neu/ErbB-2-induced breast cancer cell motility and invasion. Mol Cell Biol (2008) 1.14
Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proc Natl Acad Sci U S A (2013) 1.14
Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cells. Am J Pathol (2010) 1.13
Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. Cancer Res (2003) 1.13
Chemogenomic profiling predicts antifungal synergies. Mol Syst Biol (2009) 1.11
Histone deacetylases as transducers and targets of nuclear signaling. J Cell Biochem (2008) 1.11
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther (2010) 1.09
PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis. J Biol Chem (2009) 1.09
Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Am J Physiol Endocrinol Metab (2009) 1.08
β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression. Cancer Res (2013) 1.08
Grb2-independent recruitment of Gab1 requires the C-terminal lobe and structural integrity of the Met receptor kinase domain. J Biol Chem (2003) 1.07
Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc Natl Acad Sci U S A (2003) 1.07
Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol (2010) 1.06
Distinct ErbB-2 coupled signaling pathways promote mammary tumors with unique pathologic and transcriptional profiles. Cancer Res (2007) 1.06
Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res (2007) 1.05
Hes6 inhibits astrocyte differentiation and promotes neurogenesis through different mechanisms. J Neurosci (2006) 1.04
Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol (2011) 1.04
Rac-specific guanine nucleotide exchange factor DOCK1 is a critical regulator of HER2-mediated breast cancer metastasis. Proc Natl Acad Sci U S A (2013) 1.04
Co-encapsulation of magnetic nanoparticles and doxorubicin into biodegradable microcarriers for deep tissue targeting by vascular MRI navigation. Biomaterials (2011) 1.04
Distinct recruitment and function of Gab1 and Gab2 in Met receptor-mediated epithelial morphogenesis. Mol Biol Cell (2002) 1.04
A novel function for galectin-7: promoting tumorigenesis by up-regulating MMP-9 gene expression. Cancer Res (2005) 1.03
Crk synergizes with epidermal growth factor for epithelial invasion and morphogenesis and is required for the met morphogenic program. J Biol Chem (2002) 1.03